Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free YARW Stock Alerts

Yarrow Bioscience (YARW) Financials

$38.28 +0.33 (+0.86%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Yarrow Bioscience

Annual Income Statements for Yarrow Bioscience

This table shows Yarrow Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.61 -14 -29 -76 -98 -256 -73 -23 -28 -40 -26
Consolidated Net Income / (Loss)		 -4.61 -14 -29 -74 -95 -256 -73 -23 -28 -40 -26
Net Income / (Loss) Continuing Operations		 -4.61 -14 -29 -76 -98 -254 -44 -34 -28 -40 -27
Total Pre-Tax Income 		-4.61 -14 -30 -74 -95 -256 -45 -34 -28 -40 -27
Total Operating Income		 -4.61 -14 -30 -75 -96 -253 -39 -34 -29 -44 -30
Total Gross Profit		 0.00 0.67 4.58 3.60 0.44 20 0.93 0.48 0.42 0.50 0.57
Total Revenue		 0.00 0.67 4.58 3.60 0.44 21 0.93 0.48 0.42 0.50 0.57
Operating Revenue		 0.00 0.67 4.58 3.60 0.44 21 0.93 0.48 0.42 0.50 0.57
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 1.39 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.61 15 34 78 96 272 40 35 30 44 30
Selling, General & Admin Expense		 1.69 3.75 5.17 14 45 90 20 16 13 13 11
Research & Development Expense		 2.92 11 29 64 51 44 20 18 16 31 19
Total Other Income / (Expense), net		 0.00 0.00 0.00 -0.94 -2.36 -4.39 -5.75 0.36 1.39 3.83 3.02
Other Income / (Expense), net		 - - - 0.94 1.44 - -0.14 0.36 1.39 3.83 3.02
Income Tax Expense		 - - - 0.21 -0.18 -0.26 -0.45 0.01 0.00 0.00 0.00
Net Income / (Loss) Discontinued Operations		 - - - - - - -29 11 -0.58 -0.03 0.25
Basic Earnings per Share		 ($0.97) ($2.82) ($5.69) $11.47 $11.22 $7.88 ($25.64) ($7.28) ($2.78) ($0.93) ($0.62)
Weighted Average Basic Shares Outstanding		 4.74M 4.99M 5.11M 6.47M 8.49M 32.42M 2.86M 3.19M 10.27M 42.59M 42.77M
Diluted Earnings per Share		 ($0.97) ($2.82) ($5.69) $11.47 $11.22 $7.88 ($25.64) ($7.28) ($2.78) ($0.93) ($0.62)
Weighted Average Diluted Shares Outstanding		 4.74M 4.99M 5.11M 6.47M 8.49M 32.42M 2.86M 3.19M 10.27M 42.59M 42.77M
Weighted Average Basic & Diluted Shares Outstanding		 4.74M 4.99M 5.11M 6.47M 8.49M 32.42M 56.17M 3.26M 14.10M 15.21M 33.32M

Quarterly Income Statements for Yarrow Bioscience

This table shows Yarrow Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.58 -6.19 -6.25 -9.41 -12 -12 -8.61 -5.76 -3.59
Consolidated Net Income / (Loss)		 -6.58 -6.19 -6.25 -9.41 -12 -12 -8.61 -5.76 -3.59
Net Income / (Loss) Continuing Operations		 -6.07 -6.15 -6.24 -9.40 -12 -12 -8.60 -5.75 -3.59
Total Pre-Tax Income 		-6.07 -6.15 -6.24 -9.40 -12 -12 -8.60 -5.75 -3.59
Total Operating Income		 -6.23 -6.83 -7.38 -10 -13 -13 -9.20 -7.54 -3.82
Total Gross Profit		 0.11 0.08 0.10 0.20 0.12 0.08 0.20 0.07 0.09
Total Revenue		 0.11 0.08 0.10 0.20 0.12 0.08 0.20 0.07 0.09
Operating Revenue		 0.11 0.08 0.10 0.20 0.12 0.08 0.20 0.07 0.09
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 6.35 6.91 7.48 11 13 13 9.40 7.61 3.90
Selling, General & Admin Expense		 3.03 3.89 3.77 3.29 2.96 3.17 3.28 2.73 3.09
Research & Development Expense		 3.32 3.02 3.71 7.31 10 9.68 6.12 4.88 0.82
Total Other Income / (Expense), net		 0.16 0.68 1.14 1.00 0.93 0.76 0.59 1.80 0.23
Other Income / (Expense), net		 0.16 0.68 1.14 1.00 0.93 0.76 0.59 1.80 0.23
Income Tax Expense		 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Income / (Loss) Discontinued Operations		 -0.51 -0.04 -0.01 -0.01 0.00 -0.01 -0.01 -0.01 0.00
Basic Earnings per Share		 ($2.01) ($0.60) ($0.15) ($0.22) ($0.29) ($0.28) ($0.20) ($0.13) ($0.08)
Weighted Average Basic Shares Outstanding		 3.28M 10.27M 42.58M 42.59M 42.59M 42.59M 42.67M 42.76M 42.77M
Diluted Earnings per Share		 ($2.01) ($0.60) ($0.15) ($0.22) ($0.29) ($0.28) ($0.20) ($0.13) ($0.08)
Weighted Average Diluted Shares Outstanding		 3.28M 10.27M 42.58M 42.59M 42.59M 42.59M 42.67M 42.76M 42.77M
Weighted Average Basic & Diluted Shares Outstanding		 13.96M 14.10M 14.53M 14.75M 14.75M 15.21M 16.66M 25.47M 33.35M

Annual Cash Flow Statements for Yarrow Bioscience

This table details how cash moves in and out of Yarrow Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 44 -40 6.18 12 16 14 -16 -12 -0.30 -11 4.10
Net Cash From Operating Activities		 -4.18 -2.27 -28 -69 -73 -137 -56 -29 -25 -34 -33
Net Cash From Continuing Operating Activities		 -4.18 -2.27 -28 -69 -73 -137 -56 -29 -25 -34 -33
Net Income / (Loss) Continuing Operations		 -4.61 -14 -29 -74 -95 -256 -73 -23 -28 -40 -26
Consolidated Net Income / (Loss)		 -4.61 -14 -29 -74 -95 -256 -73 -23 -28 -40 -26
Depreciation Expense		 0.00 0.00 0.01 0.32 0.35 0.34 0.11 0.07 0.00 0.00 0.02
Amortization Expense		 0.00 0.16 0.07 - - - - 0.00 -0.26 -2.44 -0.78
Non-Cash Adjustments To Reconcile Net Income		 0.04 0.57 1.47 4.96 4.75 158 12 -8.34 3.52 3.19 2.31
Changes in Operating Assets and Liabilities, net		 0.38 11 -0.69 0.29 17 -40 4.78 2.28 -0.15 5.11 -8.19
Net Cash From Investing Activities		 0.00 -38 -15 -12 42 89 1.03 16 -57 23 37
Net Cash From Continuing Investing Activities		 0.00 -38 -15 -12 42 89 1.03 16 -57 23 37
Purchase of Property, Plant & Equipment		 0.00 -0.03 -0.03 -0.57 -1.06 -0.11 - - 0.00 -0.12 0.00
Purchase of Investments		 0.00 -55 -64 -78 -45 - - 0.00 -62 -61 -31
Sale and/or Maturity of Investments		 0.00 18 49 66 88 51 1.03 - 0.00 84 68
Net Cash From Financing Activities		 48 0.00 49 92 48 62 40 1.65 82 -0.14 -0.14
Net Cash From Continuing Financing Activities		 48 0.00 49 92 48 62 40 1.65 82 -0.14 -0.14
Other Financing Activities, net		 0.10 0.00 0.03 0.89 0.40 0.17 0.23 -0.03 -0.07 -0.14 -0.14

Quarterly Cash Flow Statements for Yarrow Bioscience

This table details how cash moves in and out of Yarrow Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 3/31/2026
Net Change in Cash & Equivalents		 -5.20 15 -12 11 -13 3.61 8.28 -6.16 0.60
Net Cash From Operating Activities		 -5.15 -5.14 -7.98 -8.48 -8.51 -9.00 -11 -11 -4.08
Net Cash From Continuing Operating Activities		 -5.15 -5.14 -7.98 -8.48 -8.51 -9.00 -11 -11 -4.08
Net Income / (Loss) Continuing Operations		 -6.58 -6.19 -6.25 -9.41 -12 -12 -8.61 -5.76 -3.59
Consolidated Net Income / (Loss)		 -6.58 -6.19 -6.25 -9.41 -12 -12 -8.61 -5.76 -3.59
Depreciation Expense		 - - 0.00 - - - 0.01 0.01 0.01
Amortization Expense		 - -0.26 -0.78 -0.62 -0.51 -0.54 -0.32 -0.21 -0.02
Non-Cash Adjustments To Reconcile Net Income		 0.86 0.93 0.98 0.89 0.74 0.58 0.76 0.53 0.47
Changes in Operating Assets and Liabilities, net		 0.57 0.38 -1.94 0.66 3.42 2.98 -3.30 -5.37 -0.96
Net Cash From Investing Activities		 - -62 -3.57 19 -4.82 13 20 4.68 4.70
Net Cash From Continuing Investing Activities		 - -62 -3.57 19 -4.82 13 20 4.68 4.70
Purchase of Investments		 - -62 -15 -6.88 -28 -10 -14 -9.58 0.00
Sale and/or Maturity of Investments		 - - 12 26 24 23 34 14 4.70
Net Cash From Financing Activities		 -0.05 83 -0.01 -0.00 -0.00 -0.13 -0.09 -0.03 -0.02
Net Cash From Continuing Financing Activities		 -0.05 83 -0.01 -0.00 -0.00 -0.13 -0.09 -0.03 -0.02
Other Financing Activities, net		 -0.05 -0.00 -0.01 -0.00 -0.00 -0.13 -0.09 -0.03 -0.02

Annual Balance Sheets for Yarrow Bioscience

This table presents Yarrow Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 42 67 140 81 94 67 41 98 67 30
Total Current Assets		 32 64 140 76 87 63 38 96 64 30
Cash & Equivalents		 4.03 10 50 44 58 42 31 31 20 24
Short-Term Investments		 27 49 87 28 1.03 - 0.00 63 42 4.98
Prepaid Expenses		 0.63 3.57 3.25 1.56 4.59 4.57 2.30 2.66 2.92 1.00
Plant, Property, & Equipment, net		 0.03 0.03 0.15 2.89 0.56 0.35 0.00 0.00 0.11 0.09
Total Noncurrent Assets		 10 2.98 0.28 1.86 5.93 3.51 2.48 1.72 2.36 0.06
Other Noncurrent Operating Assets		 0.07 - 0.28 1.86 5.93 3.51 2.48 1.72 2.36 0.06
Total Liabilities & Shareholders' Equity		 42 67 140 81 94 67 41 98 67 30
Total Liabilities		 12 15 9.55 64 56 18 9.35 8.95 15 2.40
Total Current Liabilities		 3.90 7.82 9.54 29 22 18 9.35 7.54 15 2.40
Accounts Payable		 1.53 2.46 3.29 19 4.78 6.51 2.39 1.66 2.71 1.04
Accrued Expenses		 0.58 3.56 6.25 3.38 11 8.59 4.38 4.12 9.27 0.94
Current Employee Benefit Liabilities		 - - - 5.23 4.67 2.75 2.58 1.65 1.43 0.41
Total Noncurrent Liabilities		 8.59 6.76 0.01 34 34 0.21 0.00 1.41 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -29 -57 130 18 37 49 31 89 52 28
Total Preferred & Common Equity		 -29 -57 130 18 37 49 31 89 52 28
Preferred Stock		 - 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Common Equity		 -29 -57 130 18 37 49 31 89 52 28
Common Stock		 0.70 2.21 241 328 604 688 694 780 783 785
Retained Earnings		 -30 -59 -111 -311 -566 -640 -663 -691 -731 -758
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.05 -0.10 0.01 0.00 - 0.00 0.03 0.02 0.00

Quarterly Balance Sheets for Yarrow Bioscience

This table presents Yarrow Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 3/31/2026
Total Assets		 19 92 87 76 56 45 26
Total Current Assets		 18 90 84 74 55 44 26
Cash & Equivalents		 15 19 30 16 28 22 25
Short-Term Investments		 - 67 48 54 22 18 0.30
Prepaid Expenses		 1.76 4.22 5.63 3.30 4.64 4.70 0.86
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.11 0.10 0.08
Total Noncurrent Assets		 1.76 1.45 2.87 2.66 1.40 0.27 0.00
Other Noncurrent Operating Assets		 1.76 1.45 2.87 2.66 1.40 0.27 0.00
Total Liabilities & Shareholders' Equity		 19 92 87 76 56 45 26
Total Liabilities		 7.76 8.31 12 13 12 5.84 1.24
Total Current Liabilities		 6.45 6.93 12 13 12 5.84 1.24
Accounts Payable		 0.72 2.80 4.52 3.99 3.53 1.41 0.26
Accrued Expenses		 4.45 3.64 5.07 6.17 6.86 3.58 0.89
Current Employee Benefit Liabilities		 1.28 0.38 0.74 1.07 0.52 0.82 0.09
Total Noncurrent Liabilities		 1.31 1.38 0.03 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 12 83 75 64 44 39 25
Total Preferred & Common Equity		 12 83 75 64 44 39 25
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 12 83 75 64 44 39 25
Common Stock		 697 781 782 783 784 784 786
Retained Earnings		 -685 -698 -707 -719 -740 -746 -761
Accumulated Other Comprehensive Income / (Loss)		 - -0.07 -0.06 0.03 0.00 -0.00 0.00

Annual Metrics And Ratios for Yarrow Bioscience

This table displays calculated financial ratios and metrics derived from Yarrow Bioscience's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 579.82% -21.54% -87.68% 4,638.83% -95.57% -48.76% -11.11% 18.16% 13.77%
EBITDA Growth		 0.00% -207.51% -108.32% -149.44% -27.77% -168.07% 84.56% 13.04% 16.93% -50.18% 34.93%
EBIT Growth		 0.00% -211.02% -106.48% -149.89% -27.70% -167.43% 84.54% 13.10% 17.86% -42.81% 32.84%
NOPAT Growth		 0.00% -211.02% -106.48% -153.07% -28.02% -163.42% 84.59% 11.86% 14.69% -49.15% 31.83%
Net Income Growth		 0.00% -205.30% -106.68% -155.07% -28.34% -168.52% 71.31% 68.35% -22.59% -40.00% 33.52%
EPS Growth		 0.00% -190.72% -101.77% -155.07% -28.34% -168.52% 71.31% 68.35% 61.81% 66.55% 33.33%
Operating Cash Flow Growth		 0.00% 45.85% -1,146.00% -143.30% -6.89% -86.78% 58.88% 48.20% 13.22% -34.06% 2.50%
Free Cash Flow Firm Growth		 0.00% 0.00% -1,386.06% -154.48% 12.02% -322.83% 93.39% -90.00% 41.64% -66.04% -12.94%
Invested Capital Growth		 0.00% 0.00% 13.43% 42.34% -292.75% 148.65% -118.39% 121.22% -1,143.84% -106.26% 86.82%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -73.20% 106.58% 24.65% -81.17% -35.89% 19.77% 1.62% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -59.66% 2.68% 4.85% 24.96% 2.99% 4.55% -17.02% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -62.27% 2.89% 4.84% 24.99% 3.48% 5.42% -17.26% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -64.33% 1.40% 5.76% 25.25% 2.45% 3.79% -15.75% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -71.96% 2.55% 5.42% 13.67% 6.54% 11.66% -17.16% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -71.96% 2.55% 5.42% 13.67% 6.54% 71.66% -16.25% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% -48.39% 12.31% -2.34% 21.41% 15.13% -1.30% -12.83% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 26.03% -5.73% 62.02% -14.63% -20.88% -8.43% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -1.73% -262.79% 97.71% -134.54% -90.25% -14.39% -40.85% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 93.37% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -2,102.37% -644.24% -2,048.18% -21,237.70% -1,201.38% -4,182.28% -7,098.53% -6,633.73% -8,431.54% -4,822.28%
Operating Margin		 0.00% -2,126.41% -645.85% -2,083.23% -21,641.76% -1,203.00% -4,179.48% -7,189.73% -6,900.47% -8,709.98% -5,219.12%
EBIT Margin		 0.00% -2,126.41% -645.85% -2,057.05% -21,316.70% -1,203.00% -4,193.99% -7,113.63% -6,573.58% -7,944.71% -4,689.82%
Profit (Net Income) Margin		 0.00% -2,087.24% -634.57% -2,062.95% -21,484.88% -1,217.40% -7,876.37% -4,865.83% -6,710.38% -7,950.90% -4,646.14%
Tax Burden Percent		 100.00% 98.16% 98.25% 100.29% 99.82% 99.90% 164.21% 68.40% 102.08% 100.08% 99.07%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.98% 101.30% 114.37% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -594.84% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -475.08% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 424.56% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -47.59% -71.04% -81.20% -128.66% -928.19% -170.28% -57.99% -47.36% -56.57% -66.33%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,880.86% 0.00% -6,052.17% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -34.08% -54.34% -71.52% -85.43% -288.79% -48.57% -62.95% -40.26% -48.37% -55.08%
Return on Assets (ROA)		 0.00% -33.45% -53.39% -71.73% -86.10% -292.24% -91.21% -43.06% -41.10% -48.40% -54.57%
Return on Common Equity (ROCE)		 0.00% 47.39% 75.05% -32.60% -128.66% -928.19% -170.28% -57.84% -47.28% -56.57% -66.33%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 47.78% 50.98% -56.88% -541.55% -681.64% -150.77% -74.39% -32.06% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.23 -10 -21 -52 -67 -177 -27 -24 -20 -31 -21
NOPAT Margin		 0.00% -1,488.49% -452.10% -1,458.26% -15,149.23% -842.10% -2,925.64% -5,032.81% -4,830.33% -6,096.99% -3,653.39%
Net Nonoperating Expense Percent (NNEP)		 0.00% -19.53% -16.11% -21.88% -31.73% -235.49% -119.76% 1.95% -12.83% -12.00% -12.50%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -23.08% -58.65% -75.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 6.63% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 556.53% 112.79% 389.79% 10,183.75% 426.54% 2,180.34% 3,435.43% 3,154.48% 2,633.13% 1,944.21%
R&D to Revenue		 0.00% 1,669.88% 633.06% 1,793.44% 11,558.01% 207.37% 2,099.14% 3,854.30% 3,845.99% 6,176.85% 3,374.91%
Operating Expenses to Revenue		 0.00% 2,226.41% 745.85% 2,183.23% 21,741.76% 1,296.37% 4,279.48% 7,289.73% 7,000.47% 8,809.98% 5,319.12%
Earnings before Interest and Taxes (EBIT)		 -4.61 -14 -30 -74 -94 -253 -39 -34 -28 -40 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.61 -14 -30 -74 -94 -252 -39 -34 -28 -42 -27
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.73 6.33 7.07 1.12 0.28 0.37 0.95 0.53
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.73 6.33 7.07 1.12 0.28 0.37 0.95 0.53
Price to Revenue (P/Rev)		 0.00 176.56 25.97 26.62 251.21 12.64 58.63 18.25 76.70 98.64 25.92
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 21.30 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 202.78 36.20 0.00 159.47 11.38 12.60 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 78.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 1.86 0.88 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 1.86 0.88 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.40 -1.27 -1.09 -1.20 -1.22 -0.89 -1.02 -1.03 -1.10 -1.13
Leverage Ratio		 0.00 1.42 1.33 1.13 1.49 3.18 1.87 1.35 1.15 1.17 1.22
Compound Leverage Factor		 0.00 1.42 1.33 1.13 1.51 3.22 2.14 1.35 1.15 1.17 1.22
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 65.06% 46.94% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 65.06% 46.94% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 199.59% 209.07% 0.00% 0.00% 0.00% 0.00% 0.67% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -99.59% -109.07% 100.00% 34.94% 53.06% 100.00% 99.33% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.35 -0.13 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.43 0.10 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.35 -0.13 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.49 -0.19 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.61 0.15 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.49 -0.19 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 4.39 3.27 4.30 -7.45 -13.45 -12.68 -24.09 -7.58 -14.36 -33.28
Noncontrolling Interest Sharing Ratio		 0.00% 199.59% 205.64% 59.85% 0.00% 0.00% 0.00% 0.26% 0.18% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 8.08 8.17 14.62 2.61 4.01 3.47 4.10 12.73 4.35 12.53
Quick Ratio		 0.00 7.92 7.71 14.28 2.46 3.42 2.74 3.31 12.37 4.15 12.11
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 1.73 -22 -57 -50 -211 -14 -27 -15 -26 -29
Operating Cash Flow to CapEx		 0.00% -7,306.45% -104,525.93% -12,327.47% -7,209.63% -121,311.50% 0.00% 0.00% 0.00% -29,035.90% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -54.20 -48.08 -2.49 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -79.69 -31.23 -10.05 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -80.79 -31.25 -10.05 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.02 0.08 0.03 0.00 0.24 0.01 0.01 0.01 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 2.63 0.08 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.32 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 24.96 166.62 41.32 0.29 12.21 2.05 0.00 0.00 0.00 5.62
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 138.69 4,587.40 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 1,148.49 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 3,163.86 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -1,876.67 4,587.40 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -12 -10 -5.87 -23 11 -2.06 0.44 -4.57 -9.43 -1.24
Invested Capital Turnover		 0.00 -0.11 -0.42 -0.45 -0.03 -3.54 0.20 -0.59 -0.21 -0.07 -0.11
Increase / (Decrease) in Invested Capital		 0.00 -12 1.58 4.31 -17 34 -13 2.50 -5.01 -4.86 8.19
Enterprise Value (EV)		 0.00 137 166 -41 71 239 12 -22 -61 -12 -14
Market Capitalization		 119 119 119 96 111 265 55 8.71 33 49 15
Book Value per Share		 $0.00 ($5.90) ($11.17) $5.61 $0.73 $0.22 $0.91 $0.54 $6.36 $3.53 $1.09
Tangible Book Value per Share		 $0.00 ($5.90) ($11.17) $5.61 $0.73 $0.22 $0.91 $0.54 $6.36 $3.53 $1.09
Total Capital		 0.00 30 52 130 50 71 49 31 89 52 28
Total Debt		 0.00 0.00 0.00 0.00 33 33 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 33 33 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -41 -62 -136 -41 -26 -43 -31 -93 -62 -29
Capital Expenditures (CapEx)		 0.00 0.03 0.03 0.56 1.02 0.11 0.00 0.00 0.00 0.12 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.27 -3.46 -6.29 -26 6.05 2.13 -2.05 -4.88 -12 -1.39
Debt-free Net Working Capital (DFNWC)		 0.00 28 56 130 47 65 45 29 88 50 28
Net Working Capital (NWC)		 0.00 28 56 130 47 65 45 29 88 50 28
Net Nonoperating Expense (NNE)		 1.38 4.04 8.36 22 28 79 46 -0.80 7.97 9.29 5.66
Net Nonoperating Obligations (NNO)		 0.00 -41 -62 -136 -41 -26 -51 -31 -93 -62 -29
Total Depreciation and Amortization (D&A)		 0.00 0.16 0.07 0.32 0.35 0.34 0.11 0.07 -0.26 -2.44 -0.76
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -485.31% -75.45% -175.08% -5,931.83% 28.81% 228.46% -428.72% -1,151.42% -2,374.85% -244.39%
Debt-free Net Working Capital to Revenue		 0.00% 4,100.45% 1,223.13% 3,614.91% 10,629.35% 311.98% 4,831.58% 6,064.99% 20,854.95% 9,903.79% 4,844.74%
Net Working Capital to Revenue		 0.00% 4,100.45% 1,223.13% 3,614.91% 10,629.35% 311.98% 4,831.58% 6,064.99% 20,854.95% 9,903.79% 4,844.74%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($69.84) ($203.04) ($409.68) ($170.64) ($222.48) $141.84 $25.56 ($7.28) ($2.78) ($0.93) ($0.62)
Adjusted Weighted Average Basic Shares Outstanding		 65.77K 69.27K 319.14K 323.03K 339.43K 2.85M 2.86M 3.19M 10.27M 42.59M 42.77M
Adjusted Diluted Earnings per Share		 ($69.84) ($203.04) ($409.68) ($170.64) ($222.48) $141.84 $25.56 ($7.28) ($2.78) ($0.93) ($0.62)
Adjusted Weighted Average Diluted Shares Outstanding		 65.77K 69.27K 319.14K 323.03K 339.43K 2.85M 2.86M 3.19M 10.27M 42.59M 42.77M
Adjusted Basic & Diluted Earnings per Share		 ($69.84) ($203.04) ($409.68) ($170.64) ($222.48) $141.84 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 65.77K 69.27K 70.95K 300.95K 330.82K 1.80M 3.12M 3.26M 14.10M 15.21M 33.32M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.23 -10 -21 -52 -67 -139 -27 -24 -20 -31 -21
Normalized NOPAT Margin		 0.00% -1,488.49% -452.10% -1,458.26% -15,149.23% -660.89% -2,925.64% -5,032.81% -4,830.33% -6,096.99% -3,653.39%
Pre Tax Income Margin		 0.00% -2,126.41% -645.85% -2,057.05% -21,524.61% -1,218.63% -4,796.56% -7,113.63% -6,573.58% -7,944.71% -4,689.82%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -102.53 -57.53 -6.96 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -72.87 -40.27 -4.86 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -103.64 -57.55 -6.96 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -73.97 -40.30 -4.86 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Yarrow Bioscience

This table displays calculated financial ratios and metrics derived from Yarrow Bioscience's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 3/31/2026
DEI Shares Outstanding		 3,279,971.00 13,957,324.00 14,098,888.00 14,528,247.00 14,749,397.00 14,751,433.00 15,209,862.00 16,664,892.00 33,323,171.00
DEI Adjusted Shares Outstanding		 3,279,971.00 13,957,324.00 14,098,888.00 14,528,247.00 14,749,397.00 14,751,433.00 15,209,862.00 16,664,892.00 33,323,171.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.01 -0.44 -0.44 -0.65 -0.82 -0.82 -0.57 -0.35 -0.11
Growth Metrics		 - - - - - - - - -
Revenue Growth		 -31.74% 1,166.67% -1.01% 46.67% 6.14% 10.53% 106.12% -65.15% -57.43%
EBITDA Growth		 33.17% 18.94% -25.05% 0.27% -108.58% -95.97% -27.12% 40.52% 59.68%
EBIT Growth		 34.40% 20.61% -11.21% 6.41% -100.25% -95.25% -37.85% 38.83% 58.33%
NOPAT Growth		 33.20% 14.44% -25.62% -0.76% -109.99% -86.94% -24.62% 27.45% 58.51%
Net Income Growth		 30.39% 37.78% -11.15% 6.48% -84.64% -94.28% -37.80% 38.82% 58.37%
EPS Growth		 31.63% 80.77% 91.38% 92.88% 85.57% 53.33% -33.33% 40.91% 60.00%
Operating Cash Flow Growth		 27.69% -6.78% -45.69% 11.41% -65.18% -75.18% -43.60% -27.36% 64.39%
Free Cash Flow Firm Growth		 181.69% 102.82% -246.10% -524.61% -256.74% -1,887.56% 54.05% -4.90% -190.60%
Invested Capital Growth		 -188.98% -1,143.84% 31.57% 4.40% -67.50% -106.26% -133.11% 76.66% 95.26%
Revenue Q/Q Growth		 -15.56% -33.33% 28.95% 102.04% -38.89% -30.58% 140.48% -65.84% 0.00%
EBITDA Q/Q Growth		 39.52% -5.52% -9.55% -42.65% -26.49% 0.86% 28.94% 33.25% 0.00%
EBIT Q/Q Growth		 39.52% -1.32% -1.46% -50.54% -29.40% 1.21% 28.37% 33.20% 0.00%
NOPAT Q/Q Growth		 39.58% -9.58% -8.04% -40.87% -25.92% 2.45% 27.98% 18.00% 0.00%
Net Income Q/Q Growth		 34.54% 6.01% -0.99% -50.52% -29.25% 1.11% 28.37% 33.17% 0.00%
EPS Q/Q Growth		 34.95% 70.15% 75.00% -46.67% -31.82% 3.45% 28.57% 35.00% 0.00%
Operating Cash Flow Q/Q Growth		 46.19% 0.29% -55.36% -6.28% -0.34% -5.75% -27.36% 5.74% 0.00%
Free Cash Flow Firm Q/Q Growth		 135.81% -94.47% -2,895.01% -16.41% 12.96% 36.88% 28.16% -165.78% 0.00%
Invested Capital Q/Q Growth		 -16.56% -14.39% 42.39% -24.45% -104.24% -40.85% 34.89% 87.54% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -5,325.44% -8,428.95% -7,161.22% -5,056.06% -10,465.29% -14,945.24% -4,416.34% -8,630.43% -4,182.56%
Operating Margin		 -5,468.42% -8,988.16% -7,530.61% -5,250.51% -10,819.01% -15,202.38% -4,552.97% -10,930.43% -4,437.21%
EBIT Margin		 -5,325.44% -8,093.42% -6,368.37% -4,744.95% -10,047.11% -14,297.62% -4,258.91% -8,328.99% -4,168.60%
Profit (Net Income) Margin		 -5,775.44% -8,142.11% -6,376.53% -4,750.51% -10,047.11% -14,311.90% -4,262.87% -8,340.58% -4,168.60%
Tax Burden Percent		 108.45% 100.60% 100.13% 100.12% 100.00% 100.10% 100.09% 100.14% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -5,475.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -5,466.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 5,413.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -61.16% -47.36% -52.97% -61.70% -90.62% -56.57% -66.19% -67.77% -62.40%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -56.98% -49.57% -42.44% -41.32% -103.77% -87.04% -34.80% -60.36% -45.99%
Return on Assets (ROA)		 -61.79% -49.87% -42.50% -41.37% -103.77% -87.13% -34.83% -60.44% -45.99%
Return on Common Equity (ROCE)		 -61.16% -47.28% -52.97% -61.70% -90.62% -56.57% -66.19% -67.77% -62.40%
Return on Equity Simple (ROE_SIMPLE)		 -279.96% 0.00% -34.88% 0.00% -53.51% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.36 -4.78 -5.17 -7.28 -9.16 -8.94 -6.44 -5.28 -2.67
NOPAT Margin		 -3,827.89% -6,291.71% -5,271.43% -3,675.35% -7,573.31% -10,641.67% -3,187.08% -7,651.30% -3,106.05%
Net Nonoperating Expense Percent (NNEP)		 -8.69% -2.26% -1.86% -4.31% -6.98% -3.98% -3.19% -0.81% -2.43%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.39% -6.20% -9.72% - -17.16% -14.59% -13.58% -10.84%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,657.89% 5,111.84% 3,846.94% 1,660.61% 2,449.59% 3,773.81% 1,621.29% 3,956.52% 3,587.21%
R&D to Revenue		 2,910.53% 3,976.32% 3,783.67% 3,689.90% 8,469.42% 11,528.57% 3,031.68% 7,073.91% 950.00%
Operating Expenses to Revenue		 5,568.42% 9,088.16% 7,630.61% 5,350.51% 10,919.01% 15,302.38% 4,652.97% 11,030.43% 4,537.21%
Earnings before Interest and Taxes (EBIT)		 -6.07 -6.15 -6.24 -9.40 -12 -12 -8.60 -5.75 -3.59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.07 -6.41 -7.02 -10 -13 -13 -8.92 -5.96 -3.60
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 1.15 0.37 0.52 0.38 0.44 0.95 0.54 0.71 0.81
Price to Tangible Book Value (P/TBV)		 1.15 0.37 0.52 0.38 0.44 0.95 0.54 0.71 0.81
Price to Revenue (P/Rev)		 37.43 76.70 102.33 58.89 56.25 98.64 39.72 57.77 43.86
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.99 -1.03 -1.06 -1.07 -1.14 -1.10 -1.07 -1.04 -1.09
Leverage Ratio		 1.28 1.15 1.16 1.21 1.27 1.17 1.16 1.15 1.20
Compound Leverage Factor		 1.28 1.15 1.16 1.21 1.27 1.17 1.16 1.15 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -49.09 -6.85 -6.66 -9.32 -11.46 -12.99 -16.77 -19.89 -30.83
Noncontrolling Interest Sharing Ratio		 0.00% 0.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 2.72 12.73 13.02 7.13 5.81 4.35 4.47 7.60 20.86
Quick Ratio		 2.43 12.37 12.40 6.64 5.54 4.15 4.09 6.79 20.17
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 4.13 0.23 -6.38 -7.43 -6.47 -4.08 -2.93 -7.79 -8.52
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Accounts Receivable Turnover		 0.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.75
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 371.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 371.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -4.00 -4.57 -2.63 -3.28 -6.70 -9.43 -6.14 -0.77 -0.29
Invested Capital Turnover		 1.43 -0.21 -0.13 -0.14 -0.09 -0.07 -0.14 -0.24 -0.14
Increase / (Decrease) in Invested Capital		 -8.49 -5.01 1.22 0.15 -2.70 -4.86 -3.51 2.51 5.85
Enterprise Value (EV)		 -2.25 -61 -43 -50 -43 -12 -26 -12 -5.02
Market Capitalization		 13 33 43 29 28 49 24 27 20
Book Value per Share		 $3.51 $6.36 $5.91 $5.15 $4.31 $3.53 $2.90 $2.33 $0.74
Tangible Book Value per Share		 $3.51 $6.36 $5.91 $5.15 $4.31 $3.53 $2.90 $2.33 $0.74
Total Capital		 12 89 83 75 64 52 44 39 25
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -16 -93 -86 -78 -70 -62 -50 -40 -25
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.44 -4.88 -2.71 -6.13 -9.36 -12 -7.65 -1.14 -0.38
Debt-free Net Working Capital (DFNWC)		 11 88 83 72 61 50 43 39 25
Net Working Capital (NWC)		 11 88 83 72 61 50 43 39 25
Net Nonoperating Expense (NNE)		 2.22 1.41 1.08 2.13 2.99 3.08 2.17 0.48 0.91
Net Nonoperating Obligations (NNO)		 -16 -93 -86 -78 -70 -62 -50 -40 -25
Total Depreciation and Amortization (D&A)		 0.00 -0.26 -0.78 -0.62 -0.51 -0.54 -0.32 -0.21 -0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -1,254.24% -1,151.42% -640.90% -1,260.29% -1,898.17% -2,374.85% -1,264.46% -239.50% -82.60%
Debt-free Net Working Capital to Revenue		 3,124.86% 20,854.95% 19,691.02% 14,819.34% 12,347.67% 9,903.79% 7,044.96% 8,089.71% 5,408.15%
Net Working Capital to Revenue		 3,124.86% 20,854.95% 19,691.02% 14,819.34% 12,347.67% 9,903.79% 7,044.96% 8,089.71% 5,408.15%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.01) ($0.60) ($0.15) ($0.22) ($0.29) ($0.28) ($0.20) ($0.13) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 3.28M 10.27M 42.58M 42.59M 42.59M 42.59M 42.67M 42.76M 42.77M
Adjusted Diluted Earnings per Share		 ($2.01) ($0.60) ($0.15) ($0.22) ($0.29) ($0.28) ($0.20) ($0.13) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 3.28M 10.27M 42.58M 42.59M 42.59M 42.59M 42.67M 42.76M 42.77M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.60) $0.00 $0.00 $0.00 ($0.28) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.96M 14.10M 14.53M 14.75M 14.75M 15.21M 16.66M 25.47M 33.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.36 -4.78 -5.17 -7.28 -9.16 -8.94 -6.44 -5.28 -2.67
Normalized NOPAT Margin		 -3,827.89% -6,291.71% -5,271.43% -3,675.35% -7,573.31% -10,641.67% -3,187.08% -7,651.30% -3,106.05%
Pre Tax Income Margin		 -5,325.44% -8,093.42% -6,368.37% -4,744.95% -10,047.11% -14,297.62% -4,258.91% -8,328.99% -4,168.60%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

VYNE Therapeutics’ latest quarter shows a company still in loss-making mode, but with a noticeably stronger cash position and a much lighter quarterly burn than a year ago. For Q1 2026, revenue was just $86,000, operating expenses were $3.9 million, and net loss came in at $3.6 million. That’s an improvement from the $5.8 million loss in Q2 2025 and a big improvement from the double-digit losses seen in late 2024.

Cash and liquidity are the biggest positives in the current data. VYNE ended Q1 2026 with $24.6 million in cash and equivalents and $297,000 in short-term investments, versus $22.0 million in cash and $17.6 million in short-term investments at Q2 2025. Even after burning cash from operations in Q1 2026, the company still increased cash and equivalents modestly during the quarter, helped by $4.7 million from investing activities.

However, the business remains highly dependent on external capital or investment-related cash flow. Operating cash flow was negative $4.1 million in Q1 2026, and the company has not yet shown a path to sustainable profitability. Revenue remains immaterial relative to expenses, which is typical for a development-stage biotech, but it also means results are being driven far more by R&D spending and balance-sheet management than by sales.

Here are the most important trends investors should note:

  • Q1 2026 net loss improved sharply year over year to $3.6 million from $5.8 million in Q2 2025 and $8.6 million in Q1 2025.
  • Operating cash burn also improved, with Q1 2026 operating cash outflow of $4.1 million versus $10.8 million in Q2 2025 and $11.5 million in Q1 2025.
  • Cash and equivalents rose to $24.6 million at the end of Q1 2026, up from $22.0 million in Q2 2025.
  • Balance sheet leverage remains low, with total liabilities of just $1.2 million in Q1 2026 against $24.6 million of equity.
  • R&D spending dropped meaningfully in Q1 2026 to $817,000 from $4.9 million in Q2 2025 and over $6.1 million in Q1 2025, which helped narrow losses.
  • Revenue is still minimal, with only $86,000 in Q1 2026, so the company is not yet generating meaningful operating scale.
  • Other income helped offset losses, contributing $231,000 in Q1 2026, but this is not a durable substitute for operating earnings.
  • Shares outstanding were roughly flat year over year, suggesting dilution was not a major issue in the latest quarter.
  • VYNE remains unprofitable, posting a $3.6 million net loss in Q1 2026 and negative EPS of $0.08.
  • The business still burns cash from operations, so future funding needs remain a risk if losses persist.

Longer-term pattern: compared with 2024, VYNE’s operating losses have come down substantially. In Q4 2024, the company lost $12.0 million on only $84,000 of revenue, and operating cash flow was negative $9.0 million. Since then, the quarterly loss profile has moderated, and the current quarter shows tighter expense control. That said, the company is still far from break-even, and the revenue base is too small to absorb much of the operating cost structure.

Bottom line: VYNE’s latest quarter points to improved cost discipline and a stronger liquidity position, but not to a turnaround in core profitability. For retail investors, the key question is whether the company can keep reducing burn while advancing its pipeline before cash starts to become a concern again.

08/05/26 09:21 AM ETAI Generated. May Contain Errors.

Yarrow Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Yarrow Bioscience's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Over the last 10 years, Yarrow Bioscience's net income changed from -$4.61 million in 2015 to -$26.48 million in 2025, a change of 474.7%. Find out what analysts predict for Yarrow Bioscience in the coming months.

Yarrow Bioscience's total operating income in 2025 was -$29.75 million, based on the following breakdown:
  • Total Gross Profit: $570 thousand
  • Total Operating Expenses: $30.32 million

Over the last 10 years, Yarrow Bioscience's total revenue changed from $0.00 in 2015 to $570 thousand in 2025, a change of 57,000,000.0%.

Yarrow Bioscience's total liabilities were at $2.40 million at the end of 2025, a 83.8% decrease from 2024, and a 80.8% decrease since 2016.

In the past 9 years, Yarrow Bioscience's cash and equivalents has ranged from $4.03 million in 2016 to $57.56 million in 2020, and is currently $24.03 million as of their latest financial filing in 2025.

Over the last 10 years, Yarrow Bioscience's book value per share changed from 0.00 in 2015 to 1.09 in 2025, a change of 109.0%.


Related Companies

Financial statements for NASDAQ:YARW last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel